A recent study has shown that GLP-1 drugs Which is beneficial for diabetes and weight loss, and can also protect your kidneys from damage. GLP-1 drugs include Ozempic which is prescribed for diabetes and Vegovy which is prescribed for diabetes. The study was published in The Lancet Diabetes and Endocrinology.

This is the largest study to analyze the effects of the drugs on the kidneys of people with and without diabetes. “This is the first or final study to show a clear benefit of a GLP-1 receptor agonist on kidney failure,” said Dr. Sunil Badve, a kidney specialist and professorial fellow at The George Institute for Global Health in Sydney, Australia, and lead author of the study. “Kidney disease.”

The study states that GLP-1 “has an important role in kidney-protective and heart-protective treatment for patients with common medical conditions such as type 2 diabetes, heart disease with overweight or obesity, or chronic kidney disease.”

Badway and colleagues conducted a meta-analysis of 11 large-scale clinical trials of GLP-1, involving a total of more than 85,000 people. About 68,000 people had type 2 diabetes, while more than 17,600 people were overweight or obese with heart disease but did not have type 2 diabetes.

GLP-1 drugs taken during the trials included semaglutide (Ozempic or Vegovy), dulaglutide (Trulicity) and liraglutide (Victoza).

The study found that kidney health improved in people who took the drug.

The researchers found that using GLP-1 reduced patients’ risk of kidney failure by 16% and their risk of developing kidney failure by 22%. These improvements were defined as “a decline in estimated glomerular filtration rate – a measure of how much blood the kidneys clear each minute – by at least 50%.”

“These results are especially important for patients with chronic kidney disease,” Badwe said. It is a progressive condition that eventually leads to kidney failure requiring dialysis or kidney transplantation and is associated with premature death, mostly from heart disease. “This has a significant impact on the quality of life of patients and leads to significant health care costs.”

The study also showed that the use of GLP-1 drugs reduced a person’s risk of premature death from any cause by 13%. These medicines are also beneficial for heart health. -1 reduces a person’s risk of a combination of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 14% compared with people taking a placebo.

Dr. Vlado Perkovic, Professorial Fellow at The George Institute and co-author of the study, said, “Our study has major implications for clinical guidelines for the management of chronic kidney disease and cardiovascular disease in people with and without diabetes. Will have to.”

Get the latest news live on Times Now with breaking news and top headlines from around the world.